Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block in CSVD with Dysphagia and Cognitive Impairment
NCT06176404Completed
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of lidocaine and cyanocobalamin in Cerebral Small Vessel Disease (CSVD) (2 arms). Primary endpoint: Penetration-Aspiration Scale at Day 20. Started Feb 2021; status: completed.
02
Drugs
lidocainecyanocobalamin
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT06176404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176404.